Company attributes
Other attributes
Oraya Therapeutics is a biotechnology company using non-invasive strategies to treat inflammatory and vascular diseases of the eye. The company was founded by Michael Gertner in 2007, and is headquartered in San Francisco, California.
Oraya Therapeutics is developing a stereotactic radiotherapy system called the IRay for treating wet macular degeneration and choroidal metastases (eye cancer). The IRay system uses x-ray and laser beams to target problematic regions of the optic nerve, delivering approximately a radioactive dose equivalent to 1/10 of a head CT scan.
On June 18, 2007 Oraya Therapeutics closed their series A funding round with $4 million in funding from Essex Woodlands Health Ventures.
On January 11, 2008 Oraya Therapeutics closed their series B funding round with $18 million in funding from Synergy Life Science Partner and Essex Woodlands Health Ventures.
On July 20, 2009 Oraya Therapeutics closed their series C funding round with $42 million in funding from Scale Venture Partners, Domain Associates, Essex Woodlands Health Ventures, and Synergy Life Science Partner.
On May 14, 2014 Oraya Therapeutics closed their series D funding round with $25.1 million in funding from undisclosed investors.
